This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-23 and is reviewed periodically as new material appears.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Bile acid-CoA:amino acid N-acyltransferase is an enzyme that in humans is encoded by the BAAT gene. The protein encoded by this gene is a liver enzyme that catalyzes the transfer of the bile acid moiety from the acyl-CoA thioester to either glycine or taurine, the second step in the formation of bile acid-amino acid conjugates which serve as detergents in the gastrointestinal tract.
Modelled after Umkhonto we Sizwe, the armed wing of the African National Congress, the South West African Liberation Army (SWALA) was formed by SWAPO in 1962. The first seven SWALA recruits were sent from Dar es Salaam to Egypt and the Soviet Union, where they received military instruction. Upon their return, they began training guerrillas at a makeshift camp established for housing South West African refugees in Kongwa, Tanzania.
== Conservation status == Nolina lindheimeriana does not appear on lists of endangered or threatened species, but the Flora of North America remarks that the species is infrequently found and becoming more so as its habitat is destroyed through development and overgrazing.
==== Effect on the company and bankruptcy ==== The value of the company plunged as a result of the scandal. On 24 September, Fonterra announced it had written down the carrying value of its investment by NZ$139 million (two-thirds), reflecting the costs of product recall and the impairment of the 'Sanlu' brand because of the "criminal contamination of milk". By 27 September, China Daily reported Sanlu was close to bankruptcy, and might be taken over by the Beijing Sanyuan Foods Company. The company is also facing lawsuits from parents (see Anger at Sanlu). The Beijing Review said Sanlu expects to have to pay compensation claims totalling ¥700 million, and it became clear the company would be broken up and sold. On 25 December, Shijiazhuang court accepted a creditor's bankruptcy petition against Sanlu. Media commentators expected the Sanlu distribution network to be sold.
Sources: en.wikipedia.org
An FC soldier was slightly injured in a drone attack on a post in Bannu District. A soldier from Sindh Regiment was killed in an engagement with militants near the border in Orakzai District. Five personnel from a Bomb Disposal Unit were killed in a militant attack in North Waziristan. A soldier was injured in an IED explosion in Karak District. Eight TTP militants were killed in a military IBO in Dosali. On 22 June, an insurgent commander was killed at South Waziristan-Chaman border. On 23 June, a civilian was injured in a militant drone strike on a rickshaw in Bannu District, while an FC soldier and a sweeper at a police station were abducted, the Bannu cantonment was hit twice with mortar shells. A government school in South Waziristan was destroyed by militants. Several artillery and mortar shells fired from Afghanistan hit Angoor Adda and Zalol Khel, two unexploded shells were also recovered from Bajaur District. On 24 June, a school in South Waziristan was destroyed by insurgents. Eight policemen including an SHO were abducted from South Waziristan. CTD killed six TTP militants in an operation in Lower Dir. Four TTP militants were killed in an operation near Miramshah and four more in Tank District whereas a TTP attack in Hangu District was repulsed, a soldier also died in the operation in Tank District. A quadcopter strike on a police station in Bannu District wounded two policemen whereas a school headmaster was also abducted from the district. An airstrike in South Waziristan killed two TTP insurgents.
General statistics indicate that 70–80 percent of women require direct clitoral stimulation (consistent manual, oral, or other concentrated friction against the external parts of the clitoris) to reach orgasm. Indirect clitoral stimulation (for example, by means of vaginal penetration) may also be sufficient for female orgasm. The area near the entrance of the vagina (the lower third) contains nearly 90 percent of the vaginal nerve endings, and there are areas in the anterior vaginal wall and between the top junction of the labia minora and the urinary meatus that are especially sensitive, but intense sexual pleasure, including orgasm, solely from vaginal stimulation is occasional or otherwise absent because the vagina has significantly fewer nerve endings than the clitoris. The prominent debate over the quantity of vaginal nerve endings began with Alfred Kinsey. Although Sigmund Freud's theory that clitoral orgasms are a prepubertal or adolescent phenomenon and that vaginal (or G-spot) orgasms are something that only physically mature females experience had been criticized before, Kinsey was the first researcher to harshly criticize the theory. Through his observations of female masturbation and interviews with thousands of women, Kinsey found that most of the women he observed and surveyed could not have vaginal orgasms, a finding that was also supported by his knowledge of sex organ anatomy. Scholar Janice M.
n C4H4NH + 2n FeCl3 → (C4H2NH)n + 2n FeCl2 + 2n HCl The process is thought to occur via the formation of the pi-radical cation C4H4NH+. This electrophile attacks the C-2 carbon of an unoxidized molecule of pyrrole to give a dimeric cation [(C4H4NH)2]2+. The process repeats itself many times. Conductive forms of PPy are prepared by oxidation ("p-doping") of the polymer:
Corticotropin-releasing hormone (CRH) (also known as corticotropin-releasing factor (CRF) or corticoliberin; corticotropin may also be spelled corticotrophin) is a peptide hormone involved in stress responses. It is a releasing hormone that belongs to corticotropin-releasing factor family. In humans, it is encoded by the CRH gene. Its main function is the stimulation of the pituitary synthesis of adrenocorticotropic hormone (ACTH), as part of the hypothalamic–pituitary–adrenal axis (HPA axis). Corticotropin-releasing hormone (CRH) is a 41-amino acid peptide derived from a 196-amino acid preprohormone. CRH is secreted by the paraventricular nucleus (PVN) of the hypothalamus in response to stress. Increased CRH production has been observed to be associated with Alzheimer's disease and major depression, and autosomal recessive hypothalamic corticotropin deficiency has multiple and potentially fatal metabolic consequences including hypoglycemia. In addition to the hypothalamus, CRH is produced by neurons in other brain regions, including the neocortex, limbic system and brainstem. In the olivocerebellar tract, CRH is expressed in neurons that send their axons from the inferior olivary complex to the cerebellar cortex. CRH is also synthesized in peripheral tissues, such as T lymphocytes, and it is highly expressed in the placenta, where it regulates the length of gestation and the timing of parturition and delivery.
This function shares the same values for its term in common with the Kármán–Prandtl resistance equation, plus one parameter 0.305 or 0.34 to fit the asymptotic behavior for R∗ → ∞ along with one further parameter, 26, to govern the transition from smooth to rough flow.
Sources: en.wikipedia.org
== Further reading == R. J. Mouawad, Les Maronites. Chrétiens du Liban, Brepols Publishers, Turnhout, 2009, ISBN 978-2-503-53041-3 Dr. Anis Obeid: The Druze & Their Faith in Tawhid, Syracuse University Press (July 2006). ISBN 0-8156-3097-2. Shamai, Shmuel (1990). "Critical Sociology of Education Theory in Practice: The Druze Education in the Golan". British Journal of Sociology of Education. 11 (4): 449–463. doi:10.1080/0142569900110406. Samy Swayd The Druzes: An Annotated Bibliography, Kirkland, Washington: ISES Publications (1998). ISBN 0-9662932-0-7. Salibi, Kamal S. (July 1973). "The Secret of the House of Ma'n". International Journal of Middle East Studies. 4 (3): 272–287. doi:10.1017/S0020743800031469. JSTOR 162160. S2CID 163020137.
In 1747, the Scottish surgeon James Lind discovered that citrus foods helped prevent scurvy, a particularly deadly disease in which collagen is not properly formed, causing poor wound healing, bleeding of the gums, severe pain, and death; Portuguese and Spanish sailors had independently known about the disease they acquired and how it was reduced after eating oranges and vegetables such as yams and turnips. In 1753, Lind published his Treatise on the Scurvy, which recommended using lemons and limes to avoid scurvy, which was adopted by the British Royal Navy. This led to the nickname limey for British sailors. However, during the 19th century, limes grown in the West Indies were substituted for lemons; these were subsequently found to be much lower in vitamin C. As a result, Arctic expeditions continued to be plagued by scurvy and other deficiency diseases. In the early 20th century, when Robert Falcon Scott made his two expeditions to the Antarctic, the prevailing medical theory was that scurvy was caused by "tainted" canned food. In 1881, Russian medical doctor Nikolai Lunin studied the effects of scurvy at the University of Tartu. He fed mice an artificial mixture of all the separate constituents of milk known at that time, namely the proteins, fats, carbohydrates, and salts. The mice that received only the individual constituents died, while the mice fed by milk itself developed normally.
Mary Engle Pennington (October 8, 1872 – December 27, 1952) was an American bacteriological chemist, food scientist and refrigeration engineer. She was an innovator in the preservation, handling, storage, and transportation of perishable foods and the first female lab chief at the U.S. Food and Drug Administration. She was awarded 5 patents (3 of which were shared), received the Notable Service Medal from President Herbert Hoover, and received the Garvin-Olin Medal from the American Chemical Society. She is an inductee of the National Inventor's Hall of Fame, the National Women's Hall of Fame and the ASHRAE Hall of Fame.
=== Strong magnetic fields === In magnetic fields above 10 tesla, additional plateaus of the Hall conductivity at σxy = νe2/h with ν = 0, ±1, ±4 are observed. A plateau at ν = 3 and the fractional quantum Hall effect at ν = 1/3 were also reported. These observations with ν = 0, ±1, ±3, ±4 indicate that the four-fold degeneracy (two valley and two spin degrees of freedom) of the Landau energy levels is partially or completely lifted.
=== Zika outbreak === While Zika has not been reported in India (as of 6 February 2016), on 3 February 2016, Dr Lal PathLabs and other competing pathology labs announced they were preparing Zika test kits. Dr Lal PathLabs reported they plan to sell their kits for Rs 4500 (€60). However, several days later IndiaToday reported: "the Union Ministry of Health pulled up private players, saying they cannot cash in on a public health emergency" and also reported that Dr. Vandana Lal (executive director of Dr Lal PathLabs) stated: "We don't want to talk on this matter. We don't have any tests for Zika virus and we are also not importing any test kits for the same. If at all we plan to do something, we will take the government's prior permission."
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.